Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Adachi

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Nature Communications|August 30, 2019
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodiesYu Adachi, Keisuke Tonouchi, Arnone Nithichanon, et al.
Nature Immunology|November 1, 2016
Protective neutralizing influenza antibody response in the absence of T follicular helper cellsKosuke Miyauchi, Akiko Sugimoto-Ishige, Yasuyo Harada, et al.
The Journal of Experimental Medicine|October 8, 2021
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesRyo Shinnakasu, Shuhei Sakakibara, Hiromi Yamamoto, et al.
Science Immunology|February 3, 2022
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccineRyutaro Kotaki, Yu Adachi, Saya Moriyama, et al.
Cell Reports|July 2, 2025
Antibody durability is influenced by interleukin-2 production by undifferentiated memory T helper cells and extensive B cell clonal expansionMasanori Isogawa, Masahiro Shinoda, Ryutaro Kotaki, et al.
Cell|May 18, 2019
Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent MechanismAkiko Watanabe, Kevin R McCarthy, Masayuki Kuraoka, et al.
Nature Communications|July 14, 2023
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSaya Moriyama, Yuki Anraku, Shunta Taminishi, et al.
Science Advances|June 14, 2023
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopesTaishi Onodera, Nicolas Sax, Takashi Sato, et al.
NPJ Vaccines|April 16, 2026
A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactionsTomohiro Takano, Keigo Kumagai, Hitoshi Iuchi, et al.
Communications Biology|March 23, 2025
Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variantsYuki Anraku, Shunsuke Kita, Taishi Onodera, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Nature Communications|August 30, 2019
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodiesYu Adachi, Keisuke Tonouchi, Arnone Nithichanon, et al.
Nature Immunology|November 1, 2016
Protective neutralizing influenza antibody response in the absence of T follicular helper cellsKosuke Miyauchi, Akiko Sugimoto-Ishige, Yasuyo Harada, et al.
The Journal of Experimental Medicine|October 8, 2021
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related virusesRyo Shinnakasu, Shuhei Sakakibara, Hiromi Yamamoto, et al.
Science Immunology|February 3, 2022
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccineRyutaro Kotaki, Yu Adachi, Saya Moriyama, et al.
Cell Reports|July 2, 2025
Antibody durability is influenced by interleukin-2 production by undifferentiated memory T helper cells and extensive B cell clonal expansionMasanori Isogawa, Masahiro Shinoda, Ryutaro Kotaki, et al.
Cell|May 18, 2019
Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent MechanismAkiko Watanabe, Kevin R McCarthy, Masayuki Kuraoka, et al.
Nature Communications|July 14, 2023
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariantsSaya Moriyama, Yuki Anraku, Shunta Taminishi, et al.
Science Advances|June 14, 2023
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopesTaishi Onodera, Nicolas Sax, Takashi Sato, et al.
NPJ Vaccines|April 16, 2026
A poorly reactogenic lipid nanoparticle-mRNA vaccine unveils an innate immune pathway for adverse reactionsTomohiro Takano, Keigo Kumagai, Hitoshi Iuchi, et al.
Communications Biology|March 23, 2025
Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variantsYuki Anraku, Shunsuke Kita, Taishi Onodera, et al.
Pageof 5